ALLO-501

ALLO-501 is an engineered allogeneic chimeric antigen receptor (CAR) T cell therapy targeting CD19, designed for the treatment of relapsed or refractory large B-cell lymphoma (LBCL) and follicular lymphoma. Unlike autologous CAR T therapies, ALLO-501 is derived from healthy donors and gene-edited to remove the endogenous T cell receptor (to reduce risk of graft-versus-host disease) and CD52 (to allow concurrent use of anti-CD52 antibody for lymphodepletion). The product uses TALEN gene editing technology. It is administered following a lymphodepletion regimen including fludarabine, cyclophosphamide, and ALLO-647 (an anti-CD52 monoclonal antibody). Clinical trials have shown promising efficacy with durable complete responses and a manageable safety profile in patients with relapsed/refractory LBCL who are naïve to prior CAR-T therapy[1][4][5][6][9].

Other names

Anti-CD19 AlloCAR TAnti-CD-19 AlloCAR TAnti-CD 19 AlloCAR TAnti-CD19 CAR T cell therapy - Allogene TherapeuticsAnti-CD-19 CAR T cell therapy - Allogene TherapeuticsAnti-CD 19 CAR T cell therapy - Allogene Therapeutics